New treatments for acne vulgaris over the past decade

Authors

  • Nikolas MacLellan, MD, FRCPC, DABD FACET Dermatology, Toronto, ON Sage Dermatology, Toronto, ON Rosedale Dermatology, Toronto, ON

DOI:

https://doi.org/10.58931/cdt.2024.54129

Abstract

Acne vulgaris is a prevalent, chronic inflammatory condition of the pilosebaceous units, commonly affecting adolescents and young adults, though it can persist or develop later in life. Conventional treatments such as retinoids, benzoyl peroxide, antibiotics, and hormonal therapies remain staples in managing acne vulgaris (Figure 1). Advances in the past decade have introduced novel treatments for acne vulgaris that may be more effective and tolerable for select populations.

Author Biography

Nikolas MacLellan, MD, FRCPC, DABD, FACET Dermatology, Toronto, ON Sage Dermatology, Toronto, ON Rosedale Dermatology, Toronto, ON

Dr. Niko MacLellan is a board-certified dermatologist in Canada and the United States. He completed both his Bachelor of Science degree in Biochemistry and Molecular Biology and his Doctor of Medicine at Dalhousie University, followed by his Dermatology residency at the University of Toronto where he served as co-chief resident in his final year. He holds independent licensure in Ontario and Nova Scotia, and he started practice as a locum Assistant Professor in Dalhousie University’s Division of Dermatology. He currently practices in multiple community clinics in Toronto, Ontario. He is a co-author on multiple publications in peer-reviewed journals, and is actively involved in medical education, including teaching residents and medical students in dermatology. His areas of interest include inflammatory skin conditions, skin cancer, and aesthetic dermatology.

References

Product Monograph. Health Canada website. .[Updated 2019 Nov 25; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00054047.PDF

Tan J, Chavda R, Baldwin H, Dreno B. Management of Acne vulgaris with trifarotene. J Cutan Med Surg. 2023;27(4):368-374. doi:10.1177/12034754231163542. .

ArazloTM Bausch Health, Canada Inc., Laval, QC. Product Monograph. Health Canada website. [Updated 07 Jul 2021; cited 08 Nov 2024]; https://bauschhealth.ca/wp-content/uploads/2021/07/Arazlo-PM-E-2021-07-08.pdf.

Latter G, Grice JE, Mohammed Y, Roberts MS, Benson HAE. Targeted topical delivery of retinoids in the management of acne vulgaris: current formulations and novel delivery systems. Pharmaceutics. 2019;11(10):490. doi:10.3390/pharmaceutics11100490.

Winlevi® Sun Pharma Canada Inc., Brampton ON. Product Monograph. Health Canada website. [Updated 15 Jun 2023; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00071308.PDF.

Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621-630. doi:10.1001/jamadermatol.2020.0465

Cabtreo® Bausch Health Canada Inc., Laval, QC. Product Monograph. Health Canada website. [Updated 14 Aug 2024; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00076715.PDF.

Paik J. Topical Minocycline foam 4%: a review in acne vulgaris. Am J Clin Dermatol. 2020;21(3):449-456. doi:10.1007/s40257-020-00523-1. PMID: 32468355.

Seysara® (sarecycline) tablets. Allergan, Inc. Irvine CA. U.S. Food and Drug Administration website. [Updated 01 Oct 2018; cited 08 Nov 2024]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209521s000lbl.pdf.

Graber EM. Treating acne with the tetracycline class of antibiotics: a review. Dermatol Rev. 2021;2(6):321-330. https://doi.org/10.1002/der2.49

Absorbica LD® Sun Pharma Canada Inc. Brampton ON. Product Monograph. Health Canada website. [Updated 23Aug 2023; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00071353.PDF.

Del Rosso JQ. Rationale for use of micronized isotretinoin for treatment of acne vulgaris: practical considerations and therapeutic advantages. J Clin Aesthet Dermatol. 2023;16(9):20-24.

Alexiades M, Kothare A, Goldberg D, Dover JS. Novel 1726 nm laser demonstrates durable therapeutic outcomes and tolerability for moderate-to-severe acne across skin types. J Am Acad Dermatol. 2023;89(4):703-710. doi:10.1016/j.jaad.2023.05.085

TactipumpTM andTactipumpTM Forte Galderma Canada Inc., Thornhill ON. Product Monograph. Health Canada website. [Updated 29 Jun 2018; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00046183.PDF

Differin® (XP) Galderma Canada Inc., Thornhill, ON. Product Monograph. Health Canada website. [Updated December 5, 2018; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00048625.PDF.

Benzaclin® Topical Gel Valeant Canada LP, Montreal QC. Product Monograph. Health Canada website. [Updated 29 Feb 2012; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00015735.PDF.

Taro-Clindamycin Taro Pharmaceuticals Inc., Brampton, ON. Product Monograph. Health Canada website. [Updated 19 Oct 2020.cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00058691.PDF.

BiacnaTM Topical Gel Valeant Canada Limited, Montreal QC. Product Monograph. Health Canada website. [Updated 29 Nov 2010; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00012024.PDF.

Aczone® Bausch Health, Canada Inc., Laval, QC. Product Monograph. Health Canada website. [Updated 03 Jun 2020; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00057223.PDF

Retin-A Micro® Valeant Canada LP., Laval QC. Product Monograph. Health Canada website. [Updated 21 Mar 2012; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00024577.PDF.

RanTM-Cyproterone/Ethinyl Estradiol Ranbaxy Pharmaceuticals Canada Inc., Brampton ON. Product Monograph. Health Canada website. [Updated 08 Jun 2016; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00035244.PDF

Yaz® Plus Bayer Inc., Mississauga, ON. Product Monograph. Health Canada website. [Updated 02 Mar 2017; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00038327.PDF

Alesse® 21 and Alesse® 28 Pfizer Canada Inc., Kirkland, QC. Product Monograph. Health Canada website. [Updated 26 Jun 2018; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00046064.PDF.

Tri-Cyclen® Lo Janssen Inc., Toronto, ON. Product Monograph. Health Canada website. [Updated 14 June 2018; cited 08 Nov 2024]; Available from: https://pdf.hres.ca/dpd_pm/00045949.PDF

Downloads

Published

2024-12-16

How to Cite

1.
MacLellan N. New treatments for acne vulgaris over the past decade. Can Dermatol Today [Internet]. 2024 Dec. 16 [cited 2024 Dec. 21];5(4):15–18. Available from: https://canadiandermatologytoday.com/article/view/5-4-MacLellan

Issue

Volume 5, Issue 4, Winter 2024

Section

Articles